Experience_with_multiagent_chemotherapy_for_osteosarcoma._Improved_outcome._Clinical_researches_at_the_authors'_institution_have_been_treating_patients_with_osteosarcoma_with_effective_adjuvant_chemotherapy_for_18_years,_including_14-years_experience_with_limb-salvage_surgery._The_outlook_for_patients_with_nonmetastatic_high-grade_osteosarcoma_has_improved_dramatically_since_1972._Updated_results_of_the_single-agent_adjuvant_(postoperative)_chemotherapy_trial_project_a_five-year_disease-free_survival_(DFS)_of_42%_(95%_confidence_interval_CI,_14%_to_70%)_with_follow-up_periods_of_5.7_to_13.8_years_compared_to_a_two-year_DFS_of_78%_(60%_to_95%)_and_follow-up_periods_of_0.6_to_6.8_years_with_six-agent,_alternating,_adjuvant_postoperative_chemotherapy._Additionally,_since_limb-salvage_surgery_began_to_be_offered_in_1976_to_selected_patients,_36_of_74_patients_(49%)_have_had_limb-salvage_operations_performed._The_two-year_DFS_is_69%_(52%_to_85%)_for_patients_having_limb-salvage_operations_with_follow-up_periods_of_0.6_to_10.3_years_compared_to_72%_(57%_to_87%)_for_amputees_with_follow-up_periods_of_0.3_to_10.3_years._It_is_concluded_that_patients_receiving_limb-salvage_operations_appear_to_be_at_no_greater_risk_for_relapse_than_patients_receiving_cross-bone_amputation_and_that_the_administration_of_alternating,_multiagent,_adjuvant_chemotherapy_has_significantly_improved_the_DFS_for_patients_who_present_with_nonmetastatic_high-grade_osteosarcoma.